Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gilliland

Showing results (121-130 of 182) with videos related to

Pageof 19
Sort By:
Molecular Cancer Therapeutics|July 11, 2007
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cellsEllen Weisberg, Andrew L Kung, Renee D Wright, et al.
Blood|July 19, 2011
Differential niche and Wnt requirements during acute myeloid leukemia progressionSteven W Lane, Yingzi J Wang, Cristina Lo Celso, et al.
Haematologica|May 25, 2010
Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesisSumin Koo, Brian J Huntly, Yuan Wang, et al.
Nature Genetics|November 13, 2007
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesisGang Huang, Pu Zhang, Hideyo Hirai, et al.
Nature Structural Biology|May 29, 2002
The CCPN project: an interim report on a data model for the NMR communityRasmus Fogh, John Ionides, Eldon Ulrich, et al.
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Blood|June 10, 2011
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specificationMelanie G Cornejo, Vinciane Mabialah, Stephen M Sykes, et al.
Cancer Cell|June 28, 2002
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemiaAdolfo A Ferrando, Donna S Neuberg, Jane Staunton, et al.
Blood|July 5, 2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyAnimesh Pardanani, Rhett P Ketterling, Stephanie R Brockman, et al.
Blood|July 27, 2006
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsAnimesh D Pardanani, Ross L Levine, Terra Lasho, et al.
Pageof 19

Showing results (121-130 of 182) with videos related to

Sort By:
Pageof 19
Molecular Cancer Therapeutics|July 11, 2007
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cellsEllen Weisberg, Andrew L Kung, Renee D Wright, et al.
Blood|July 19, 2011
Differential niche and Wnt requirements during acute myeloid leukemia progressionSteven W Lane, Yingzi J Wang, Cristina Lo Celso, et al.
Haematologica|May 25, 2010
Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesisSumin Koo, Brian J Huntly, Yuan Wang, et al.
Nature Genetics|November 13, 2007
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesisGang Huang, Pu Zhang, Hideyo Hirai, et al.
Nature Structural Biology|May 29, 2002
The CCPN project: an interim report on a data model for the NMR communityRasmus Fogh, John Ionides, Eldon Ulrich, et al.
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Blood|June 10, 2011
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specificationMelanie G Cornejo, Vinciane Mabialah, Stephen M Sykes, et al.
Cancer Cell|June 28, 2002
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemiaAdolfo A Ferrando, Donna S Neuberg, Jane Staunton, et al.
Blood|July 5, 2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyAnimesh Pardanani, Rhett P Ketterling, Stephanie R Brockman, et al.
Blood|July 27, 2006
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsAnimesh D Pardanani, Ross L Levine, Terra Lasho, et al.
Pageof 19